About Us
Corporate Overview
Executive Leadership
Management team
Scientific Advisory Board
Board of Directors
Clinical Advisory Board
Our Science
Pipeline
Overview
AG-73305
AG-80308
AG-86893
Disease
Overview
DME
nAMD
Other Diseases
Pterygium
Dry Eye
Clinical Trial
Investor Relations
Investors
Press Release & Publications
Allgenesis In The News
Contact Us
News
2023-11-09
鼓舞人心的AG-73305臨床 2a試驗數據顯示了初步安全性和有效性
Read more
2023-11-09
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema at American Academy of Ophthalmology
Read more
2023-09-30
Allgenesis to Present Initial Data from Phase 2a Study of AG-73305, a Novel Bispecific Anti-VEGF and Anti-Integrin Fc-Fusion Protein for the Treatment of DME at AAO 2023
Read more
2023-06-19
Allgenesis Announces Encouraging Phase 1b Data Showing AG-80308 Providing Improvements in Multiple Signs and Symptoms in Dry Eye Patients
Read more
2023-05-29
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema
Read more
